Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sudden Cardiac Death.

Roy M. John1

  • 1Lahey Clinic Medical Center.

Current Treatment Options in Cardiovascular Medicine
|August 25, 2004
PubMed
Summary
This summary is machine-generated.

Implantable cardioverter-defibrillators (ICDs) improve survival for malignant ventricular arrhythmias. While effective for secondary prevention, their role in primary sudden cardiac death prevention requires careful consideration of individual risk factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Area of Science:

  • Cardiology
  • Electrophysiology
  • Genetics

Background:

  • Sudden cardiac death (SCD) is frequently caused by ventricular arrhythmias.
  • Malignant arrhythmias, without transient causes, indicate a high risk of recurrence and SCD.
  • Survival rates for out-of-hospital cardiac arrest remain critically low (1-5%).

Purpose of the Study:

  • To review the role of implantable cardioverter-defibrillators (ICDs) in the primary and secondary prevention of sudden cardiac death (SCD).
  • To evaluate the efficacy of ICDs in various patient populations, including those with coronary artery disease (CAD) and nonischemic dilated cardiomyopathy.
  • To discuss the current understanding of genetic factors contributing to primary electrical abnormalities and SCD.

Main Methods:

  • Review of clinical trial data on ICD therapy versus antiarrhythmic drug therapy for malignant arrhythmias.

Related Experiment Videos

  • Analysis of patient subgroups based on left ventricular ejection fraction (LVEF) and presence of nonsustained ventricular tachycardia.
  • Examination of preliminary data regarding ICD use in nonischemic dilated cardiomyopathy and the impact of heart failure symptoms.

    • Main Results:

    • ICD therapy demonstrates a uniform survival benefit compared to drug therapy in survivors of malignant arrhythmias.
    • In CAD patients, ICDs reduce mortality with LVEF < 30%. For LVEF 30-40%, inducible ventricular arrhythmia identifies benefit.
    • Preliminary data suggest ICDs may prevent SCD in nonischemic dilated cardiomyopathy patients with heart failure symptoms.

    Conclusions:

    • ICDs are effective for secondary prevention of SCD.
    • The role of ICDs in primary prevention is less clear and varies by underlying condition (e.g., CAD vs. nonischemic cardiomyopathy) and individual risk factors.
    • Pharmacological agents targeting beta-adrenergic stimulation, angiotensin, and aldosterone can reduce mortality, partly by mitigating SCD risk.